Purity Analysis¶
HPLC Purity and Impurity Profiling¶
Introduction¶
Purity analysis by reversed-phase HPLC (RP-HPLC) with UV detection at 214 nm is the primary method for quantifying peptide purity. The 214 nm wavelength corresponds to the absorption maximum of the peptide bond, providing a uniform response factor across different peptide sequences. Purity values derived from HPLC are reported as area percent — the integrated area of the main peak divided by the total area of all peaks in the chromatogram.
It is critical to distinguish between area percent (HPLC purity) and weight percent (absolute peptide content). Area percent reflects the relative abundance of the peptide species among all UV-absorbing components, whereas weight percent accounts for water, residual solvents, and counter-ions. A peptide may appear ≥98% pure by HPLC area yet contain only 80% peptide by weight. Both metrics are reported on the certificate of analysis.
HPLC Purity Calculation¶
Purity by HPLC area percent is calculated as:
Where: - A_main = integrated area of the principal peptide peak - Σ A_all = sum of integrated areas of all peaks (excluding void volume, system peaks, and solvent front)
System Suitability Requirements¶
| Parameter | Requirement |
|---|---|
| Theoretical plates (main peak) | ≥5000 |
| Tailing factor | 0.8–1.8 |
| Resolution (main peak from nearest impurity) | ≥1.5 |
| RSD of retention time (5 replicate injections) | ≤1.0% |
| RSD of peak area (5 replicate injections) | ≤2.0% |
| Signal-to-noise (0.1% impurity standard) | ≥10:1 |
| Blank injection | No interfering peaks |
Impurity Profiling and Thresholds¶
Individual impurities are reported when their peak area exceeds the reporting threshold. The following thresholds align with ICH Q3A/Q3B guidance adapted for peptide drug substances:
| Purity Range | Report Threshold | Identify Threshold | Qualify Threshold |
|---|---|---|---|
| ≥98% | ≥0.05% | ≥0.10% | ≥0.15% |
| 95–98% | ≥0.10% | ≥0.15% | ≥0.20% |
| <95% | ≥0.15% | ≥0.25% | ≥0.50% |
Routine Impurity Categories¶
| Impurity Type | Typical RT Relative to Main Peak | Common Level (%) | Origin |
|---|---|---|---|
| Deletion sequences | 0.70–0.95 (earlier) | 0.05–2.0 | Incomplete coupling during SPPS |
| Truncated peptides | 0.65–0.90 (earlier) | 0.02–1.0 | Failed deprotection |
| D-isomers | 0.95–1.05 (shoulder) | 0.1–5.0 | Racemization during coupling |
| Oxidation products | 0.80–0.95 (earlier) | 0.05–0.5 | Met or Trp air oxidation |
| Dimer/aggregates | 1.05–1.30 (later) | 0.1–2.0 | Post-cleavage assembly |
| Scavenger residues | 0.30–0.60 (early) | 0.02–0.5 | Cleavage cocktail carryover |
Acceptance Criteria¶
| Application | HPLC Purity (Area %) | Single Largest Impurity | Total Impurities | Reporting |
|---|---|---|---|---|
| Research use | ≥95% | ≤3.0% | ≤5.0% | All ≥0.1% |
| In vivo studies | ≥98% | ≤1.0% | ≤2.0% | All ≥0.05% |
| Clinical GMP (Phase I–III) | ≥98% | ≤1.0% | ≤2.0% | All ≥0.05% |
| Diagnostic (IVD) | ≥98% | ≤1.0% | ≤2.0% | All ≥0.05% |
| Custom requirement | Per CoA specification | As agreed | As agreed | Per agreement |
Interpretation Guide¶
A purity result of 98.5% with a single 0.8% impurity and no other peak above 0.05% indicates a well-purified peptide. The impurity at 0.8% should be identified if manufacturing consistency requires it. A purity result of 95.2% with multiple 0.2–0.5% impurities suggests a batch that may benefit from additional preparative HPLC purification.
When purity falls below specification, review the impurity profile to determine whether a dominant process-related impurity (e.g., a specific deletion product) can be minimized by adjusting synthesis conditions, or whether the impurity profile indicates broad, low-level contamination requiring more fundamental changes.
Common Issues¶
- Co-eluting impurities: Impurities that co-elute with the main peak inflate apparent purity. Use PDA peak purity analysis or MS detection to verify single-component peak status.
- Gradient-related baseline drift: A rising or falling baseline can distort integration. Use blank gradient subtraction and consistent integration parameters.
- Overloaded injection: Injecting >50 µg of peptide on a 4.6 mm ID column broadens peaks and under-estimates impurities. Maintain column loading at or below 20–30 µg.
🔗 Related: HPLC Analysis | LC-MS Testing | COA Understanding | Custom Peptide Synthesis OEM Manufacturing Quality Standards